The aim of this study was to understand by which intrahepatic mechanism metformin (Met) may inhibit basal hepatic glucose production (HGP) in type 2 diabetes. We studied rats that were fed for 6 weeks a high-fat (HF) diet, supplemented (HF-Met) or not (HF) with Met (50 mg ⅐ kg ؊1 ⅐ day ؊1 ). Basal HGP, assessed by 3-[ 3 H]glucose tracer dilution, was lower by 20% in HFMet rats compared with HF-rats: 41.6 ؎ 0.7 vs. 52 ؎ 1.5 mol ⅐ kg ؊1 ⅐ min ؊1 (means ؎ SE, n ؍ 5; P < 0.01). Glucose-6 phosphatase (Glc6Pase) activity, assayed in a liver lobe freeze-clamped in situ, was lower by 25% in HF-Met rats compared with HF-rats (7.9 ؎ 0.4 vs. 10.3 ؎ 0.9 mol ⅐ min ؊1 ⅐ g ؊1 wet liver; P < 0.05). Glucose-6 phosphate and glycogen contents, e.g., 42 ؎ 5 nmol/g and 3.9 ؎ 2.4 mg/g, respectively, in HF-rats were dramatically increased by three to five times in HF-Met rats, e.g., 118 ؎ 12 nmol/g and 19.6 ؎ 4.6 mg/g (P < 0.05 and P < 0.01, respectively). Glucose-6 phosphate dehydrogenase activity was increased in HF-Met compared with HF rats (1.51 ؎ 0.1 vs. 1.06 ؎ 0.08 mol ⅐ min ؊1 ⅐ g ؊1 ; P < 0.01). Intrahepatic lactate concentration tended to be lower in the Met-group (؊30%; NS), whereas plasma lactate concentration was higher in HF-Met rats (1.59 ؎ 0.15 mmol/l) than in HF rats (1.06 ؎ 0.06 mmol/l; P < 0.05). We concluded that Met decreases HGP in insulin-resistant HF-fed rats mainly by an inhibition of hepatic Glc6Pase activity, promoting glycogen sparing. Additional mechanisms might involve the diversion of glucose-6 phosphate into the pentose phosphate pathway and an inhibition of hepatic lactate uptake. Diabetes 51:139 -143, 2002
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.